GSK plc
Company & revenue
About GSK plc
Who they are
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally.
Detailed revenue, brand and relationship research has not yet been completed for GSK.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
40
Weak
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
67
Fair
Financial Strength
83
Business Quality / Moat
43
Management
95
Growth Quality
31
Risk / Durability
82
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
42
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
47/100
Building Historical Record
Model Score 47/100 — estimates relative performance potential, distinct from WallStreetScore (company quality).
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
WSS currently sees meaningful weaknesses in the company-strength profile.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Balance-sheet / debt profile scores strongly
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for GSK
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can GSK maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is GSK's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is GSK's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What future growth or profitability would be needed to justify GSK's current valuation?
- •What does the current fundamental change risk warning mean for the reliability or interpretation of GSK's score?
Essential Investment Snapshot
Wall Street Score
40
Opportunity Score
42
Market Cap
$94.22B
P/E Ratio
15.1
EPS
$3.18
52-Week High
$61.70
52-Week Low
$42.85
Beta
0.29
Intrinsic Value
$50.40
Analyst Target
$60.00
Shares Outstanding
2.06B
Total Revenue
$44.05B
Total Debt
$24.05B
Dividend Yield
3.45%
Liquidation Value / Share
$11.00
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for GSK
Detected from reported data — verify before acting.Dividend history reported
The provider reports a dividend yield. Confirm the latest declaration before treating it as a current payment.
Community Sentiment
0 active · 0 total callsNo personal call yet on GSK.
What the Bulls Say
- +Product opportunity: GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The.
- +Positive free cash flow may provide capacity to invest in growth.
What the Bears Say
No strong bearish data point is currently available.
Bull and bear cases summarize disclosed catalysts, growth opportunities and risks; they are not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
4 historical score records availablePrevious Score
39
Sep 28, 2026
Change
+1.3
points
Current Score
40
Oct 1, 2026
Category Changes
GSK increased 1.3 points because Capital improved by 2 points, Valuation improved by 4.9 points.
Positive Contributors
- + Capital improved by 2 points
- + Valuation improved by 4.9 points
Projected Score
Projected Score
37
Projected Change
-3.2%
Preliminary comparable-period financial changes suggest decline of approximately 3.2 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Near Fair ValueCurrent Price
$47.03
Intrinsic Value
$50.40
Difference
−$3.37
-6.7% vs IV
Margin of Safety
6.7%
Related Companies
Drug Manufacturers - GeneralNews
Wave Life Sciences Announces GSK's Selection of siRNA program to Transition to GSK for Further Development
GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential?
GSK retains ‘buy' rating at Jefferies as B7H3 cancer programme seen as underappreciated
Merck, Daiichi Withdraw FDA Filing for Lung Cancer Therapy
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial